TY - JOUR
T1 - Characterizing progression to neovascular amd in fellow eyes of patients treated with intravitreal anti-vegf injections
AU - Starr, Matthew R.
AU - Xu, David
AU - Boucher, Nicholas
AU - Saroj, Namrata
AU - Patel, Luv G.
AU - Ammar, Michael
AU - Pandit, Ravi R.
AU - Jenkins, Thomas L.
AU - Ho, Allen C.
N1 - Funding Information:
Originally submitted June 25, 2020. Revision received October 24, 2020. Accepted for publication January 26, 2021. Presented in part at The Wills Eye Hospital Annual Conference, March 5, 2020, Philadelphia, Pennsylvania, and presented at the American Society of Retina Specialists Annual Meeting, July 27, 2020, Seattle, Washington. Dr. Saroj is a consultant for Apellis and RegenxBio, has equity in Pr3vent, and is a consultant for and has equity in Allegro and SamaCare. Dr. Ho is a consultant for Genentech and has received financial support from Allergan, Alcon, and Iconic. The remaining authors report no relevant financial disclosures. Drs. Starr and Xu contributed to this manuscript equally as co-first authors. Address correspondence to Allen C. Ho, MD, Mid Atlantic Retina, Retina Service of Wills Eye Hospital, 840 Walnut St., Suite 1020, Philadelphia, PA 19107; email: acho@midatlanticretina.com. doi: 10.3928/23258160-20210302-02
Publisher Copyright:
© 2021 Slack Incorporated. All rights reserved.
PY - 2021
Y1 - 2021
N2 - BACKGROUND AND OBJECTIVE: The purpose of this study was to assess the real-world incidence of conversion to bilateral neovascular age-related macular degeneration (nAMD) following treatment initiation of nAMD in the initial eye. PATIENTS AND METHODS: This was a retrospective cohort of electronic health records from retinal centers across the United States (Vestrum Database) of all patients with unilateral nAMD treated with anti-vascular endothelial growth factor therapy. RESULTS: A total of 22,553 patients with unilateral nAMD were included. Fellow eyes of 8,522 patients (38%) converted to nAMD. Among these, 2,639 (12%), 2,030 (9%), and 1,802 (8%) patients converted in Years 1, 2, and 3, respectively, after diagnosis in the first eye. Fellow eyes had better vision at conversion and 1 year following conversion. CONCLUSIONS: The fellow eye should be monitored at regular intervals to detect signs of neovascularization. Fellow eyes presented with significantly better vision at diagnosis than the initial eye and maintained better visual acuity with less injections.
AB - BACKGROUND AND OBJECTIVE: The purpose of this study was to assess the real-world incidence of conversion to bilateral neovascular age-related macular degeneration (nAMD) following treatment initiation of nAMD in the initial eye. PATIENTS AND METHODS: This was a retrospective cohort of electronic health records from retinal centers across the United States (Vestrum Database) of all patients with unilateral nAMD treated with anti-vascular endothelial growth factor therapy. RESULTS: A total of 22,553 patients with unilateral nAMD were included. Fellow eyes of 8,522 patients (38%) converted to nAMD. Among these, 2,639 (12%), 2,030 (9%), and 1,802 (8%) patients converted in Years 1, 2, and 3, respectively, after diagnosis in the first eye. Fellow eyes had better vision at conversion and 1 year following conversion. CONCLUSIONS: The fellow eye should be monitored at regular intervals to detect signs of neovascularization. Fellow eyes presented with significantly better vision at diagnosis than the initial eye and maintained better visual acuity with less injections.
UR - http://www.scopus.com/inward/record.url?scp=85105579958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105579958&partnerID=8YFLogxK
U2 - 10.3928/23258160-20210302-02
DO - 10.3928/23258160-20210302-02
M3 - Article
C2 - 34038686
AN - SCOPUS:85105579958
VL - 52
SP - 123
EP - 128
JO - Ophthalmic Surgery Lasers and Imaging Retina
JF - Ophthalmic Surgery Lasers and Imaging Retina
SN - 2325-8160
IS - 3
ER -